Eisai Announces Data Presentations on KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Investigational Combination Therapy and HALAVEN® (eribulin) at ESMO 2019
Advertisement
- Data includes an oral presentation from full advanced endometrial carcinoma (EC) cohort of Phase 1b/2 study of KEYTRUDA plus LENVIMA